Development of an improved preclinical humanized mouse platform representing the diverse clinical phenotypes of Sjögren’s syndrome - Scorecard - MDSpire

Development of an improved preclinical humanized mouse platform representing the diverse clinical phenotypes of Sjögren’s syndrome

  • By

  • Jin-Sil Park

  • JeongWon Choi

  • Ha Yeon Jeong

  • Hye Yeon Kang

  • Sang Hee Cho

  • Su Beom Lee

  • Mi-La Cho

  • Sung-Hwan Park

  • May 22, 2026

  • 0 min

Share

Clinical Scorecard: Creation of an Enhanced Humanized Mouse Model to Reflect the Varied Clinical Manifestations of Sjögren’s Syndrome

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with Sjögren’s syndrome, including specific demographics such as age and gender.
Care Setting

Key Highlights

  • Add a highlight on the model's potential for future research or clinical applications.

Guideline-Based Recommendations

Diagnosis

    Management

    • Evaluation of therapeutic strategies such as metformin in preclinical models.
    • Consideration of other treatment options based on patient response.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clarify if metformin is recommended for all SS patients or only in specific cases.

        Clinical Best Practices

        • Expand on the rationale for using humanized models for studying autoimmune diseases.

        Related Resources & Content

        Original Source(s)

        Development of an improved preclinical humanized mouse platform representing the diverse clinical phenotypes of Sjögren’s syndrome

        • by Jin-Sil Park, JeongWon Choi, Ha Yeon Jeong, Hye Yeon Kang, Sang Hee Cho, Su Beom Lee, Mi-La Cho, Sung-Hwan Park

        • May 22, 2026

        Related Content

        Successful treatment of refractory focal eosinophilic myositis with extra-ocular muscle involvement using tocilizumab: a case report

        RA Outcomes Improved in KURAMA Cohort

        Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

        MiR-1a-3p/Fcgr4-dependent osteoclast activation regulates pathological bone loss